Revenue (GAAP) increased 11.1% to $6.0 billion, above analyst expectations. Adjusted earnings per share rose 11.4% to $3.13, exceeding consensus estimates. Full-year 2025 guidance was raised for both ...

The medtech firm, which previously forecast a $200 million tariff impact for 2025, also raised its earnings outlook, citing ...

Stryker’s financials revealed total sales of $3.7bn in its medical surgery and neurotechnology business unit, up 17.3% on Q2 ...

Q2 2025 Management View Kevin A. Lobo, Chair, CEO & President, highlighted, "We delivered double-digit organic sales growth of 10.2% and adjusted EPS growth of 11.4% while managing through the impacts ...

Stryker raised its annual profit forecast and beat quarterly profit estimates on Thursday, banking on strong demand for its medical and surgical devices. Medical and surgical device makers have ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $429.5, a high estimate of $455.00, and a low estimate of $400.00. Marking an increase of 3.18%, the ...

Stryker reached a key milestone with its Mako robotics, Jason Beach, vice president of finance and investor relations, said in a July 31 earnings call. During the second quarter Stryker reached 2 ...

This was the stock's fifth consecutive day of losses.

Stryker sells two product lines, OP-1 and Calstrux, for reconstructing bones damaged by surgery or injury. The products actively recruit new blood supply, promote bone growth, and fill voids in bones.